Related Experiment Video
Updated: Oct 21, 2025
A 3D Organotypic Melanoma Spheroid Skin Model
Published on: May 18, 2018
Targeting cyclin-dependent kinase 4/6 as a therapeutic approach for mucosal melanoma
Chao-Ji Shi1,2, Sheng-Ming Xu1,2,3, Yong Han1,2,3
1Department of Oral and Maxillofacial-Head Neck Oncology, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine.
Abstract:
Mucosal melanoma is a rare but devastating subtype of melanoma which typically has a worse prognosis than other melanoma subtypes. Large-scale next-generation sequencing studies, including our recent research, have also proved that the molecular landscape and potential oncogenic drivers of mucosal melanoma remain distinct from that of cutaneous melanoma. Recently, a number of selective cyclin-dependent kinase 4 (CDK4)/6 inhibitors have been approved for clinical application in breast cancer or entered phase III clinical trial in other solid tumors. Additionally, we have revealed that the dysregulation of cell cycle progression, caused by CDK4 amplification, is a key genetic feature in half of mucosal melanoma and targeting of CDK4 in selected mucosal melanoma patients is a potentially promising direction for precision cancer treatment by using molecular-characterized mucosal melanoma patient-derived-xenograft models. This review summarizes the current literature regarding CDK4/6 dysregulation in mucosal melanoma, preclinical and clinical studies of CDK4/6 inhibitors and potential combinational strategies in treating mucosal melanoma.
Insights
Mucosal melanoma, distinct from cutaneous melanoma, shows CDK4 amplification in half of cases. Targeting cyclin-dependent kinase 4 (CDK4)/6 offers a promising precision treatment strategy for this rare cancer.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- Mucosal melanoma is a rare melanoma subtype with a poor prognosis and distinct molecular drivers compared to cutaneous melanoma.
- Cyclin-dependent kinase 4 (CDK4)/6 inhibitors are emerging therapeutics with approved indications and ongoing clinical trials in various cancers.
- CDK4 amplification is a key genetic alteration found in approximately 50% of mucosal melanoma cases, highlighting its role in disease progression.
Purpose of the Study:
- To review the current literature on CDK4/6 dysregulation in mucosal melanoma.
- To summarize preclinical and clinical studies evaluating CDK4/6 inhibitors for mucosal melanoma treatment.
- To explore potential combination strategies for enhancing therapeutic efficacy.
Main Methods:
- Literature review of studies on CDK4/6 dysregulation and inhibitors in mucosal melanoma.
- Analysis of next-generation sequencing data identifying genetic drivers.
- Evaluation of patient-derived xenograft models for therapeutic targeting.
Main Results:
- CDK4 amplification is a significant genetic feature in a substantial proportion of mucosal melanoma.
- Targeting CDK4 presents a viable precision medicine approach for selected patients.
- Preclinical data supports the efficacy of CDK4/6 inhibitors in mucosal melanoma models.
Conclusions:
- Dysregulation of the cell cycle via CDK4 amplification is a critical oncogenic event in mucosal melanoma.
- Targeting CDK4/6 is a promising therapeutic avenue for precision cancer treatment in mucosal melanoma.
- Further research into combination therapies may improve outcomes for patients with this rare cancer.
Related Concept Videos
02:34Inhibition of Cdk Activity
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:15M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
02:38Mitogens and the Cell Cycle